Journal profile · Medicine-Oncology
Cancer Pathogenesis and Therapy
ISSN 2097-2563 · eISSN 2949-7132 · Elsevier · Netherlands
Cancer Pathogenesis and Therapy: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 5.9 (journal website); fully open access; APC about USD 2,700; median 97 days to acceptance (72 articles, last 24 months); 51 articles a year; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Cancer Pathogenesis and Therapy (CPT) is an international open access journal covering key topics in all aspects of cancer research, focusing on mechanism innovation, emerging interdisciplinary and clinical trials research in Oncology. As a Chinese Medical Association (CMA) journal, it strives to publish the highest quality content that provides authoritative guidance to oncology specialists, physicians and researchers.CPT is dedicated to publishing innovative and significant research results in basic research, translation research and clinical oncology, including novel antitumor drugs, especially clinical trials, early screening/prevention, precise diagnosis and targeted therapy, interdisciplinary oncology innovation research and clinical translation in genetics, bioinformatics, pharmacology, and biology, and also new viewpoints, new ideas, new methods and new models of cancer prevention and public health policy.CPT regularly features news and expert interviews to promote expert oncologists' views on oncology guidelines, consensus , and education.CPT is concerned about, but not limited to, the following academic scopes: Basic Cancer Research, Clinical Cancer Research, Cancer prevention and public health policy, Oncological Pharmacology, Cancer Genomics, Cancer Informatics, Anticancer drug discovery, Artificial Intelligence, etc.The article types for CPT include: Research article, Review article, Editorial, Guideline and Consensus, Perspective, Case report, Technical note, Letter to the Editor, etc.P-ISSN 2097-2563
From the journal's Aims & Scope
Research area (LetPub): Medicine-Oncology
Editor-in-chief David James KerrPublisher website
Editorial board by country: 49 in mainland China (about 72%); most named Mainland China 49, United States 7, Italy 3, Malaysia 3, Hong Kong, China 2 (68 members with a country) Editorial board ↗Publisher website ·
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 5.9Publisher website ·
- CiteScore 2026-06
- 6.2LetPub ·
- CiteScore (publisher)
- 6.2Publisher website ·
- SJR 2026-06
- 0.89LetPub ·
- SNIP 2026-06
- 0.8LetPub ·
- Self-citation rate
- 8.5%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 51LetPub ·
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
97 daysMedian, submission to acceptance · P25–P75 72 days – 156 days
- Acceptance to online
- median 4 days (72 articles)
- Submission to online
- median 101 days
- Sample
- 72 articles with submission and acceptance dates (105 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 8 weeksLetPub ·
- Submission to first decision
- 1 daysPublisher website ·
- First decision after review
- 26 daysPublisher website ·
- Submission to acceptance
- 105 daysPublisher website ·
- Submission to publication (journal-reported)
- about 48 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,700 | Yes | CC BY, CC BY-NC-ND | |
| LetPub | USD 1,100 | Yes | — | |
| Publisher website | USD 2,700 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers1, by deadline
Publisher websiteWhat to prepare6 items from the author guidelines
- Abstract
- ≤ 500 words
- Keywords
- ≥ 3
- Manuscript length
- ≤ 5,000 words
- Reference style
- AMA
- Highlights
- Optional
- Graphical abstract
- Optional
Article types accepted7, with length limits
- case reportn the figure legend or table notes. (8) Case Report Word limit: 2000 words maximum including abstract but excluding references, tablesmain text ≤ 2,000 words
- commentarythe figure legend or table notes. (11) Commentary Word limit: 2000 words maximum excluding references. Abstract: not required. Refermain text ≤ 2,000 words
- editorialnsolicited editorials are also welcome. Editorials can be up to 2000 words length with no more than 15 references. Word Limit: 2000 womain text ≤ 2,000 words
- letter to the editorn the figure legend or table notes. (9) Letter to the Editor Word limit: 1500 words maximum. Abstract: not required. References: 15 maximum. Ifmain text ≤ 1,500 words
- original articleseries, and in vitro study.The text of original articles amounting to about 5000 words (excluding abstract, references and figures/tables) shouldmain text ≤ 5,000 words
- perspectiveer to the type of Research Article. (6) Perspective Personal views are welcome and the length should be about 2000 words (not including tables, figures, and ref…main text ≤ 2,000 words
- technical noten the figure legend or table notes. (7) Technical Note Word limit: 2000 words including abstract but excluding references, tables and figmain text ≤ 2,000 words
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, License & copyright, Open access, Peer review, Preprints, Trial registration / reporting guidelines
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- Data availability
PRISMA reporting guidelines encouraged Model summary
For systematic reviews and meta-analyses you are encouraged to follow the PRISMA reporting guidelines.
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing allowed Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
Source ↗Publisher website ·- Trial registration / reporting guidelines Reporting Guidelines for Specific Study Designs
CONSORT (Randomized controlled trials) STARD (Studies of diagnostic accuracy) QUOROM (Systematic reviews and meta-analyses) STROBE (Observational studies in epidemiology) MOOSE (Meta-analyses of observational studies in epidemiology)
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- Netherlands
- Language
- English
- ISSN
- 2097-2563
- Electronic ISSN
- 2949-7132
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Cancer Pathogenesis and Therapy
What CAS zone is Cancer Pathogenesis and Therapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cancer Pathogenesis and Therapy is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cancer Pathogenesis and Therapy?
The journal's website gives an impact factor of 5.9; this is the journal's own figure, as LetPub lists none for it; CiteScore 6.2.
How long does peer review take at Cancer Pathogenesis and Therapy?
Based on the dates recorded on 72 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 97 days (interquartile range 72–156 days); authors report an average review time of about 8 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Cancer Pathogenesis and Therapy?
According to the journal's author guidelines: Abstract: ≤ 500 words; Keywords: ≥ 3; Manuscript length: ≤ 5,000 words; Reference style: AMA; Highlights: Optional; Graphical abstract: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Cancer Pathogenesis and Therapy based?
Of the 68 board members whose country the journal's board page names, 49 (about 72%) are in mainland China; the countries named most often are Mainland China (49), United States (7) and Italy (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Cancer Pathogenesis and Therapy?
According to LetPub and DOAJ records, Cancer Pathogenesis and Therapy is indexed in ESCI, Scopus and DOAJ.
Is Cancer Pathogenesis and Therapy open access, and what is the APC?
Cancer Pathogenesis and Therapy is a fully open-access journal. APC about USD 2,700.
Sources and updates
The facts on this page come from LetPub, Publisher website, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .